This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Patients with Crohn's disease who continue advanced therapies, including biologics and small-molecule drugs, in the months before elective colorectal surgery may have a lower risk of two postoperative complications: anastomotic leak and organ space surgical site infection, according to a study published in the Journal of the American College of Surgeons.
These findings challenge previous thoughts that immunosuppressive therapies should be stopped before surgery due to concerns about postoperative complications. In contrast, advanced therapy use was associated with improved outcomes and a lower risk of anastomotic leak and organ space surgical site infection, feared complications of colorectal surgery.
The retrospective analysis from 2021 to 2024 includes 1,150 patients at 24 centers in the American College of Surgeons NSQIP-Inflammatory Bowel Disease Collaborative. After adjusting for baseline differences, anastomotic leak or organ space surgical site infection occurred in 2.43% of patients who received advanced therapy compared with 6.46% of those who did not. There was no statistically significant difference in superficial surgical site infection, deep incisional surgical site infection, or wound dehiscence.
Crohn's disease is a chronic inflammatory condition of the digestive tract that often requires surgical removal of diseased areas of the lower digestive system and reconnection of the remaining intestine, called an anastomosis. An anastomotic leak, in which a hole forms at the reconnection and poop leaks into the abdomen, is a potentially devastating complication that can require emergency reoperation or prolonged hospitalization.
Source link







